Características de los pacientes con neoplasias hematológicas y con tumores sólidos atendidos por un equipo de soporte paliativo hospitalario / Characteristics of patients with hematological and solid tumors malignancies attended by a hospital palliative care service

Antecedentes y objetivo: El interés por la atención paliativa en pacientes con neoplasias hematológicas está aumentando. Nuestro objetivo es describir las características de pacientes oncológicos valorados por un equipo de soporte paliativo en un hospital terciario y analizar las diferencias entre pacientes hematológicos y con tumores sólidos. Método: Estudio observacional descriptivo longitudinal retrospectivo con una cohorte de pacientes hospitalizados con enfermedad oncológica (hematológica o tumor sólido) valorados por equipo de soporte paliativo hospitalario. Comparamos variables clínicas, asistenciales y de supervivencia. El análisis de datos se realizó con la versión 15 del programa SPSS. Resultados: De enero de 2015 a diciembre de 2018 se valoraron 1025 pacientes oncológicos (10,8 % hematológicos, 89,2 % sólidos). No se encontraron diferencias en situación funcional medida por la Palliative Performance Scale, presentación de síntoma principal, porcentaje de pacientes con dolor, tiempo de seguimiento ni en porcentaje de fallecidos en el ingreso en que fueron valorados. El paciente hematológico, comparado con el oncológico, tiene menos tratamiento opioide pautado (43 vs. 53 %; p = 0,035), es seguido con más frecuencia por recurso paliativo hospitalario que domiciliario (46,55 vs. 29,44 % el primero; 15,5 vs. 33,06 % el segundo; p = 0,001 en distribución) y fallece más en hospital (82,9 vs. 65,5 %; p = 0,024). Conclusiones: Los pacientes con neoplasia hematológica presentan una carga sintomática similar a los pacientes con tumor sólido. Es importante identificar mejor sus necesidades para que puedan beneficiarse, como se ha demostrado con los pacientes oncológicos, de la atención integrada junto a los servicios de hematología con modelos de intervención acordes a sus necesidades y las trayectorias específicas de las enfermedades hematológicas. (AU)

Background and objective: Interest in palliative care for patients with hematologic malignancies is increasing. Our goal is to describe the features of cancer patients evaluated by a supportive and palliative care service in a tertiary referral hospital, and to analyze the differences between patients with hematological malignancies and solid tumors. Method: A retrospective longitudinal descriptive observational study was carried out in a cohort of hospitalized patients with oncological diseases (hematological or solid tumor) evaluated by a palliative care service. We compared clinical, healthcare and survival variables between both groups. The analysis was performed using the SPSS v.15 package. Results: From January 2015 to December 2018, 1025 cancer patients were evaluated (10.8 % hematological tumor, 89.2 % solid tumors). No differences were found in functional status as measured by the Palliative Performance Scale, presentation of main symptom, percentage of patients with pain, time of follow-up, or percentage of deaths on admission to the evaluation. The hematological patient, compared to the oncological one, has less prescribed opioid treatment (43 % vs 53 %, p = 0.035), received greater hospital palliative care rather than home-based care (46.55 % vs 29.44 % the former and 15.5 % vs 33.06 % the latter, p = 0.001), and dies more frequently in a hospital (82.9 % vs. 65.5 %, p = 0.024). Conclusions: Patients with hematological malignancies present a symptomatic burden similar to that of those with solid tumors. It is important to better identify their needs so that they can benefit, as has been demonstrated with cancer patients, from integrated care together with hematology services using intervention models according to their needs and specific disease trajectories. (AU)

Determinants of mortality in cancer patients with unscheduled admission to the Intensive Care Unit: A prospective multicenter study / Factores determinantes de la mortalidad en pacientes con cáncer ingresados de forma no programada en la Unidad de Cuidados Intensivos: estudio multicéntrico prospectivo

Objectives To analyze clinical fatures associated to mortality in oncological patients with unplanned admission to the Intensive Care Unit (ICU), and to determine whether such risk factors differ between patients with solid tumors and those with hematological malignancies. Design An observational study was carried out. Setting A total of 123 Intensive Care Units across Spain. Patient All cancer patients with unscheduled admission due to acute illness related to the background oncological disease. Interventions None. Main variables Demographic parameters, severity scores and clinical condition were assessed, and mortality was analyzed. Multivariate binary logistic regression analysis was performed. Results A total of 482 patients were included: solid cancer (n=311) and hematological malignancy (n=171). Multivariate regression analysis showed the factors independently associated to ICU mortality to be the APACHE II score (OR 1.102; 95% CI 1.064–1.143), medical admission (OR 3.587; 95% CI 1.327–9.701), lung cancer (OR 2.98; 95% CI 1.48–5.99) and mechanical ventilation after the first 24h of ICU stay (OR 2.27; 95% CI 1.09–4.73), whereas no need for mechanical ventilation was identified as a protective factor (OR 0.15; 95% CI 0.09–0.28). In solid cancer patients, the APACHE II score, medical admission, antibiotics in the previous 48h and lung cancer were identified as independent mortality indicators, while no need for mechanical ventilation was identified as a protective factor. In the multivariate analysis, the APACHE II score and mechanical ventilation after 24h of ICU stay were independently associated to mortality in hematological cancer patients, while no need for mechanical ventilation was identified as a protective factor. Neutropenia was not identified as an independent mortality predictor in either the total cohort or in the two subgroups (AU)

Objetivos Determinar las características clínicas asociadas con la mortalidad en pacientes oncológicos ingresados de forma no programada en la UCI. También evaluamos si estos factores de riesgos difieren en los pacientes con neoplasias hematológicas o tumores sólidos. Diseño Estudio observacional. Ámbito Ciento veintitrés Unidades de Cuidados Intensivos en España. Pacientes Todos los pacientes con cáncer ingresados de forma no programada debido a una enfermedad aguda asociada con la enfermedad oncológica. Intervenciones Ninguna. Variables principales Las variables analizadas fueron los datos demográficos, escalas pronósticas de gravedad y el estado clínico del paciente. Se analizó la mortalidad y los factores relacionados con ésta. Se aplicó un análisis de regresión logística binaria multivariante. Resultados Se incluyó a un total de 482 pacientes: con tumores sólidos (n=331) y con neoplasias hematológicas (n=171). En el análisis de regresión multivariante, los factores asociados de manera independiente con la mortalidad en la UCI fueron la puntuación APACHE II (OR 1,102; IC del 95% 1,064-1,143), el ingreso médico (OR 3,587; IC del 95% 1,327-9,701), el cáncer de pulmón (OR 2,98, IC del 95% 1,48-5,99) y la ventilación mecánica tras las primeras 24h de ingreso en la UCI (OR 2,27; IC del 95% 1,09-4,73), mientras que la no necesidad de ventilación mecánica fue un factor protector (OR 0,15; IC del 95% 0,09-0,28). En el caso de los tumores sólidos, la puntuación APACHE II, el ingreso médico, la administración de antibióticos en las 48 h previas y el cáncer de pulmón fueron variables independientes relacionadas con la mortalidad, y la no necesidad de ventilación mecánica se identificó como un factor protector. En el análisis multivariante, la puntuación APACHE II y la ventilación mecánica al cabo de 24h desde el ingreso en la UCI se asociaron de manera independiente con mortalidad en pacientes con neoplasias hematológicas (AU)

Determinants of mortality in cancer patients with unscheduled admission to the Intensive Care Unit: A prospective multicenter study.

OBJECTIVES: To analyze clinical features associated to mortality in oncological patients with unplanned admission to the Intensive Care Unit (ICU), and to determine whether such risk factors differ between patients with solid tumors and those with hematological malignancies. DESIGN: An observational study was carried out. SETTING: A total of 123 Intensive Care Units across Spain. PATIENTS: All cancer patients with unscheduled admission due to acute illness related to the background oncological disease. INTERVENTIONS: None. MAIN VARIABLES: Demographic parameters, severity scores and clinical condition were assessed, and mortality was analyzed. Multivariate binary logistic regression analysis was performed. RESULTS: A total of 482 patients were included: solid cancer (n=311) and hematological malignancy (n=171). Multivariate regression analysis showed the factors independently associated to ICU mortality to be the APACHE II score (OR 1.102; 95% CI 1.064-1.143), medical admission (OR 3.587; 95% CI 1.327-9.701), lung cancer (OR 2.98; 95% CI 1.48-5.99) and mechanical ventilation after the first 24h of ICU stay (OR 2.27; 95% CI 1.09-4.73), whereas no need for mechanical ventilation was identified as a protective factor (OR 0.15; 95% CI 0.09-0.28). In solid cancer patients, the APACHE II score, medical admission, antibiotics in the previous 48h and lung cancer were identified as independent mortality indicators, while no need for mechanical ventilation was identified as a protective factor. In the multivariate analysis, the APACHE II score and mechanical ventilation after 24h of ICU stay were independently associated to mortality in hematological cancer patients, while no need for mechanical ventilation was identified as a protective factor. Neutropenia was not identified as an independent mortality predictor in either the total cohort or in the two subgroups. CONCLUSIONS: The risk factors associated to mortality did not differ significantly between patients with solid cancers and those with hematological malignancies. Delayed intubation in patients requiring mechanical ventilation might be associated to ICU mortality.

Impacto clínico y epidemiológico de la infección por SARS-CoV-2 en pacientes adultos con tumores sólidos / Clinical and epidemiological impact of SARS-CoV-2 infection in adult patients with solid tumors

La infección por SARS-CoV-2 en pacientes con cáncer puede ser severa y con importante mortalidad. Diseñamos un estudio prospectivo observacional que tuvo como objetivo describir el impacto clínico y epidemiológico de la infección por SARS-CoV-2 en pacientes con tumores sólidos. Se incluyeron 27 pacientes con neoplasias activas, con una mediana de edad de 72 años, y mediana de score de Charlson de 6. Las infecciones fueron de adquisición nosocomial en 18,5% de los pacientes, y el 74% tuvo infiltrados pulmonares, con una alta proporción de patrón mixto y consolidativo en imágenes. Casi la mitad de los pacientes tuvo enfermedad severa y crítica. Presentaron complicaciones e infecciones hospitalarias el 26% y 14,8% respectivamente. La mortalidad a 30 días fue de 25,9%, mayormente relacionada al COVID-19. La infección por SARS-CoV-2 en nuestra población tuvo considerable impacto clínico y epidemiológico

SARS-CoV-2 infection in cancer patients can be severe, and with significant mortality. We performed a prospective observational study to describe the clinical and epidemiological impact of SARS-CoV-2 infection in solid tumors patients. Twenty-seven patients with active neoplasms were included, with a median age of 72 and a median Charlson score of 6. Infections were nosocomially acquired in 18.5% of the patients, and 74% had pulmonary infiltrates, with a high proportion of mixed and consolidative pattern in images. Almost half of the patients had a severe and critical illness. Twenty-six percent and 14.8% had complications and hospital infections, respectively. The 30-day mortality was 25.9%, mostly related to COVID-19. SARS-CoV-2 infection in our population had a considerable clinical and epidemiological impacto

Desarrollo de modelos educativos para el aprendizaje de nuevas técnicas endoscópicas: miotomía endoscópica por vía oral (POEM) y elastografía por ultrasonido endoscópico / Educational models for learning Peroral Endoscopic Myotomy (POEM) and Endoscopic Ultrasound Elastography

Resumen Objetivos: presentar el desarrollo de modelos educativos para el aprendizaje de dos técnicas endoscópicas vigentes, ampliamente difundidas y de gran implicación clínica, con la única intención de permitir la adquisición de destrezas básicas y avanzadas a residentes y gastroenterólogos. Materiales y métodos: se idearon dos modelos sencillos, de muy bajo costo, fácilmente reproducibles y reutilizables, con los cuales se logra ejecutar la totalidad de los procedimientos descritos. Además, permiten al operador integrar el desarrollo de habilidades y la adquisición de los conceptos teóricos mínimos requeridos, sin las presiones generadas por el riesgo existente de complicaciones. Resultados: la tendencia actual a nivel mundial se conduce hacia el desarrollo de modelos de enseñanza que aceleren la curva de aprendizaje, así como de procedimientos altamente exigentes y asociados a complicaciones potencialmente graves. Con estos modelos es posible poner a prueba al endoscopista, mediante una evaluación continua y supervisada. Su implementación en unidades de gastroenterología es sencilla, sin la necesidad de una inversión superlativa o el desplazamiento a otros países. Conclusiones: se trata de un gran aporte al desarrollo científico y educativo de nuestro país, ya que la creación y la implementación de nuevas técnicas endoscópicas y su aprendizaje no deben ser asumidos por los pacientes. En este punto, estamos de acuerdo con los conceptos emitidos por diferentes asociaciones médicas respecto a que los cursos teórico-prácticos de corta duración -y en algunas ocasiones virtuales- no constituyen una formación mínima, requerida para lograr la acreditación.

Abstract Objectives: This article presents the development of educational models for learning two widespread recent endoscopic techniques which have great clinical implications. Its sole intention is to allow acquisition of basic and advanced skills by residents and gastroenterologists. Materials and methods: Two simple, very low cost, easily reproducible and reusable models were devised. Procedures are fully described in ways that allow the operator to integrate the development of skills and acquisition of the minimum theoretical concepts required without the pressures generated by risks of complications. Results: The current global trend is to develop teaching models that accelerate the learning curve for highly demanding procedures that are associated with potentially serious complications. With these models it is possible to test endoscopists through continuous supervised evaluations. Implementation by gastroenterology units can be done easily without the need for large investments or travel to other countries. Conclusions: This is a great contribution to the scientific and educational development of Colombia since neither development of new endoscopic techniques nor the process of learning how to perform them should put patients at risk. We agree with the ideas of numerous medical associations regarding theoretical-practical courses of short duration even though some virtual sessions, "do not constitute the minimum training required needed for accreditation".

Crecimiento postraumático en pacientes sobrevivientes de cáncer infantil / (Posttraumatic growth in pediatric oncologic patients)

Resumen Objetivo: Estudiar el crecimiento postraumático en sobrevivientes pediátricos de linfoma o tumores sólidos, tratados en el Servicio de Oncología del Hospital Nacional de Niños, de enero de 1990 a diciembre 2013. Métodos: Este es un estudio descriptivo con pacientes sobrevivientes de cáncer quienes se encontraban en remisión, por un tiempo mayor o igual a 5 años. Se analizó las características clínicas de los pacientes (sexo, lugar de residencia, edad, tipo y localización del tumor, tratamiento recibido, presencia de metástasis o recaída), así como se efectuó una entrevista sobre la condición psicosocial de los sobrevivientes, con énfasis en las consecuencias de la enfermedad en su vida actual. Resultados: Se analizaron las características clínicas de 30 pacientes sobrevivientes. Se encontró que el tipo de tumor más común en el grupo entrevistado fue el linfoma no Hodgkin (30 %), seguido de sarcomas (20 %). Las localizaciones tumorales mayormente observadas en estos pacientes fueron en cabeza y cuello (46,7 %), seguidas por abdomen y pelvis (26,7 %). El tratamiento más frecuente fue la combinación de quimioterapia, radioterapia y cirugía (37,7 %). Pero cabe resaltar que el 80 % de los pacientes tratados recibió quimioterapia como parte de su tratamiento y la mayoría reportó efectos adversos y dificultades relacionadas. El procedimiento quirúrgico más empleado fue la biopsia (53,3 %). La mayoría de los pacientes no presentó recaídas (83,3 %) ni metástasis (93,3 %). Con respecto a su condición actual, la edad promedio al momento de la entrevista fue de 15,9 años, y la mayoría residía en la provincia de San José (40 %), con sus padres y hermanos (36,7 %). La mayoría señaló reacciones positivas ante el diagnóstico, con actitudes buenas y cooperadoras. El mayor vínculo socioafectivo descrito corresponde a la familia y los amigos; un grupo importante de los pacientes recalca el apoyo institucional. Conclusiones: A pesar de que con este trabajo no se pueden realizar generalizaciones sobre los pacientes en remisión de cáncer infantil, la información obtenida permite conocer de manera indirecta el impacto psicosocial de la enfermedad oncológica en la condición actual de un grupo de pacientes, y resalta una actitud positiva en los sobrevivientes.

Abstract Objective: To study resilience (post-traumatic growth) in pediatric cancer survivors who were treated in the Oncology Service of the National Children's Hospital, from January 1990 to December 2013. Methods: descriptive study with cancer survivors who were in remission, for a time greater tan or equal to 5 years. The clinical characteristics of the patients (sex, place of residence, age, type and location of the tumor, treatment received, presence of metastasis or relapse) were analyzed, as well as an interview on the psychosocial condition of the survivors, with emphasis on the consequences of the disease in their current life. Results: 30 survivors of childhood cancer were interviewed and the clinical characteristics were analized. Among the results, the most common type o tumor found was non Hodgkin lymphoma (30%), followed by sarcomas (20%). The tumor locations mostly observed in these patients were in the head and neck (46.7%), followed by the abdomen and pelvis (26.7%). The most frequent treatment was the combination of chemotherapy, radiotherapy and surgery (37.7%). But it should be noted that 80% of treated patients received chemotherapy as part of their treatment and the majority reported adverse effects and related difficulties. The most widely used surgical procedure was biopsy (53.3%). The majority of patients had no relapses (83.3%) or metastases (93.3%). Regarding their current condition, the average age at the time of the interview was 15.9 years, and the majority resided in the province of San José (40%), with their parents and siblings (36.7%). The majority indicated positive reactions to the diagnosis, with good and cooperative attitudes. The greatest socio-affective link described during their disease corresponds to family and friends and hospital health workers. Conclusions: Although, with this work, generalizations cannot be made about patients in remission of childhood cancer, the information obtained allows us to indirectly know the psychosocial impact of the oncological disease in the current condition of a group of patients in our country, and highlights a positive attitude in survivors.

Second neoplasms in adult patients submitted to haematopoietic stem cell transplantation. / Segundas neoplasias en pacientes adultos receptores de un trasplante de progenitores hematopoyéticos.

BACKGROUND AND OBJECTIVE: Patients submitted to haematopoietic stem cell transplantation (HSCT) are at increased risk of late complications, such as second neoplasm (SN). The incidence and risk factors of SN in patients receiving HSCT at a single centre were analysed. PATIENTS AND METHODS: The follow-up of adult patients who received a first HSCT (autologous [auto-HSCT] or allogeneic [allo-HSCT]) between January 2000 and December 2015 was reviewed. We collected their demographic characteristics, the primary disease and type of HSCT, and analysed the cumulative incidence of SN and their risk factors. RESULTS: Of 699 transplanted patients (auto-HSCT, n=451; allo-HSCT, n=248), 42 (6%) developed SN (17 haematological and 25 solid), 31 post-auto-HSCT and 11 post-allo-HSCT. Haematologic SN were more frequent after auto-HSCT than after allo-HSCT. The median time between HSCT and SN was 4.09 years [range 0.07-13.15], with no differences between auto-HSCT and allo-HSCT. The cumulative incidence of SN was 5% (95% CI 3-6) at 5 years, 7% (95% CI 5-10) at 10 years and 11% (95% CI 8-15) at 15 years, without differences according to the type of HSCT. Only the age over 40 years correlated with an increased risk of SN. CONCLUSIONS: In this series, the incidence of post-HSCT SN was similar to that previously described. Patients submitted to an auto-HSCT showed a higher frequency of haematologic SN. A higher incidence of SN was detected in patients older than 40 at the time of HSCT.

Tumor lysis syndrome in solid tumors: Clinical characteristics and prognosis. / Síndrome de lisis tumoral en neoplasias sólidas: características clínicas y pronóstico.

INTRODUCTION AND OBJECTIVE: Tumour lysis syndrome (TLS) is an uncommon complication in solid tumors following treatment initiation, and its spontaneous development (STLS) is exceptional. In this study, we analyse the main clinical and prognostic features of a case series with TLS and STLS. MATERIAL AND METHODS: Observational retrospective study in which we included all patients with solid tumours diagnosed with TLS and STLS over a period of 16 years, according to Cairo-Bishop criteria. RESULTS: Nineteen patients were included in the study (mean age 63±16 years): 10 patients (53%) with TLS, and 9 (47%) STLS. The primary tumour in 8 cases (42%) was lung cancer. All patients had severe renal impairment at the time of diagnosis along with hyperuricemia (16±6mg/dl) and hyperkalemia (6±0.9mmol/l). Despite treatment with intravenous fluids, urinary alkalinisation and rasburicase, 3 patients (16%) required dialysis, and 12 (63%) died during the follow-up period. CONCLUSIONS: The development of TLS in solid tumors is associated with increased mortality and therefore, a high index of suspicion is essential for early diagnosis and treatment initiation.

Estudio de una masa abdominal en pediatría: revisión de la literatura / Study of an abdominal mass in pediatrics: review of the literature

Alrededor del 20 por ciento de los tumores diagnosticados en pediatría corresponden a masas intraabdominales y de ellos, el 20 por ciento son tumores malignos, por lo que un alto índice de sospecha asociado a un diagnóstico precoz pueden incidir positivamente en el pronóstico de los pacientes. El objetivo de este trabajo fue realizar una revisión actualizada de la literatura disponible sobre el estudio de una masa abdominal en pediatría, enfocado principalmente en la epidemiología y orientación diagnóstica que debería seguir el médico al enfrentarse a un paciente con este hallazgo. La forma de presentación clínica de una masa abdominal es variable. En un número importante de pacientes será de forma asintomática, lo que dificulta el diagnóstico precoz, por lo que es necesario mantener un alto índice de sospecha frente esta patología. Como herramientas para la evaluación de una masa abdominal contamos cada vez más con exámenes radiológicos, marcadores tumorales e histología, sin embargo, los exámenes deben realizarse orientados a comprobar la sospecha diagnóstica que obtengamos de una completa anamnesis y examen físico.

About 20 percent of the tumors diagnosed in pediatric patients correspond to intraabdominal masses. These can correspond to both benign and malignant pathology. Moreover, 20 percent of solid malignant tumors are located in the abdomen, so a high index of suspicion associated with an early diagnosis can positively affect the prognosis of these patients. The clinical presentation of an abdominal mass is variable. A significant number of patients will be asymptomatic, which makes early diagnosis difficult. This is why it is necessary to maintain a high index of suspicion in this pathology. As tools for the evaluation of an abdominal mass, we are increasingly counting on radiological examinations, tumor markers and histology. However, the examinations must be carried out in order to verify the diagnostic suspicion that we obtain from a complete anamnesis and physical examination. The objective of this work was to perform an updated review of the available literature on the study of abdominal mass in pediatrics, focused mainly on the epidemiology and diagnostic orientation that should be followed by the physician when confronting a patient with this finding.

"17 años después": Tumores sólidos infantiles es hoy un reto interminable

Introducción: El objetivo del estudio fue conocer el número de casos de cada tumor hubo en un periodo de quince años (1999-2014) y el porcentaje de pacientes supervivientes a julio del 2016 y que continúan asistiendo a consultas de seguimiento. Materiales y métodos: Se revisaron los datos registrados en cuanto al diagnóstico de tumores sólidos en niños en Panamá de cuatro bases de datos diferentes ocurridos desde 1999 hasta el 2014. Se calculó el porcentaje de pacientes que hasta julio del 2016 están vivos y asistiendo a consultas de seguimiento.Resultados: 672 pacientes fueron diagnosticados con tumores sólidos, con edades al momento del diagnóstico entre un mes y 15 años. De ellos 52% viven y están el seguimiento sin patología oncológica. De los casos registrados el 41% son tumores cerebrales y el 58.9% corresponden a tumores sólidos no cerebrales, susceptibles a manejo quirúrgico como tumor de Wilms, neuroblastoma, rabdomiosarcoma, osteosarcoma, tumores hepáticos y tumores germinales. Un 8.9% de todos los casos corresponden a retinoblastoma. Conclusiones: Se reflexiona acerca mejoras futuras entre las cuales: la sospecha temprana y referencia efectiva, la priorización de cupos para citas cuando hay sospecha de un cáncer y la conciencia social sobre el cáncer infantil son claves para el éxito.

Introduction: The aim of the study was to determine the incidence of each tumor was in a period of fifteen years (1999-2014 ) and the percentage of patients surviving July 2016 and continue to attend follow-up visits. Material and methods: Reviewed four different data base for the registry of new cases of pediatric tumors in fifteen year in Panama (1999-2014). Was calculed the percentage of patients who still alive until July 2016 and attending follow-up visits was calculated Results: 672 pediatrics patients were diagnosed in the range of age al diagnosis between 1-month old and 15 years. We found that 52% are actually alive and in follow-up to the moment that this paper is finished. The 41% of cases are tumors of the central nervous system, 58.9% of the cases are visceral solid tumors prone to surgical management such as Wilms tumor, Neuroblastoma, Germ-Cell tumors, rabdomiosarcoma, hepatic tumors and 8.9% are retinoblastomas. Conclusion: A reflection of future measures made us propose: early detection and prompt reference efforts, the attention of premonitory case for the suspicion of pediatric tumor and the advocacy of the social conscience for the problem of childhood cancer.

Predição volumétrica de lesões pulmonares aplicando modelo oculto de Markov / Prediction volumetric of lung lesions applying hidden Markov model

OBJETIVO: predizer o estado volumétrico de lesões pulmonares aplicando o modelo oculto de Markov (HMM). MATERIAIS E MÉTODOS: Aquisição de imagens de lesões pulmonares temporais, geração do HMM e a aplicação do HMM. RESULTADOS: Os testes foram aplicados em 24 lesões pulmonares, adquiridas da Public Lung Database to Address Drug Response (PLDADR). Dividimos os resultados desta pesquisa em 3. O primeiro utilizando a base completa para predição volumétrica da lesão e comparação com o Response Evaluation Criteria in Solid Tumors (RECIST), atingindo uma taxa de acerto de 70,83%. No segundo, Aplica - se o método leave-one-out, separando os dados em dois grupos, treino e teste, obtendo-se uma taxa de acerto de 75,00%. Por fim, realizamos a predição volumétrica de cada lesão no intervalo de 5 tempos. O resultado mostrou que é possível predizer se o estado da lesão está progredindo, regredindo ou estabilizando, a partir das alterações ocorridas nos diâmetros e volumes.

OBJECTIVE: predicting the volume status of lung lesions by applying the hidden Markov model (HMM). MATERIALS AND METHODS: Acquisition of images of temporal lung lesions, HMM generation and application of HMM. RESULTS: The tests were applied in 24 pulmonary lesions, acquired from Public Lung Database to Address Drug Response(PLDADR). We have divided this search in 3. The first using the full volumetric basis for prediction of the lesion and compared to the Response Evaluation Criteria in Solid Tumors (RECIST), reaching a 70.83% success rate. Then, weapply the leave-one-out method, separating the data into two groups, training and testing, yielding a 75.00% successrate. Finally, we volumetric prediction of each lesion in 5 days interval. The result showed that it is possible to predict the state of the injury is progressing, regressing or stabilizing, from changes in the diameters and volumes.

[RECIST and the radiologist]. / RECIST y el radiólogo.

Biomedical imaging makes it possible not only to diagnose and stage cancer, but also to follow up patients and evaluate the response to treatment. RECIST (Response Evaluation Criteria In Solid Tumors) provides a method to monitor the response to treatment based on one dimensional measurements of tumors obtained with reproducible imaging techniques like CT, MRI, and PET. The metabolic changes induced by new treatments modify the biology and behavior of the tumor; occasionally, there is a discrepancy between the patient's clinical condition and the response measured by RECIST, which indicates that functional tests need to be included in the evaluation of the response to treatment. The objective is to review the RECIST criteria to include the contribution of functional imaging to enable the efficacy and effects of the treatment in patients with solid tumors.

[Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors]. / Irinotecán y temozolomida en tumores sólidos pediátricos en recaída o refractarios.

INTRODUCTION: The prognosis of refractory or relapsed pediatric solid tumors is very poor, and there is no standard treatment for this condition. The combination of irinotecan and temozolomide has proved useful in adults as a second-line treatment of different solid tumors. In pediatric patients, this combination has been effective in Ewing's sarcoma, neuroblastoma, and relapsed or refractory rhabdomyosarcoma. PATIENTS AND METHODS: A retrospective study was conducted on 32 pediatric patients with refractory or relapsed solid tumors, who were treated with irinotecan and temozolomide in the Oncology Department at Children's Hospital Niño Jesus from September 2005 to June 2012. The clinical characteristics, treatment performed, toxicity and outcome, were analyzed. RESULTS: Thirty-two patients received a total of 180 cycles. Of the 30 evaluable patients, 10 (33%) had a positive response (2 complete remission and 8 partial remission), and in 8 (27%) the disease remained stable. Almost all (94%) of the patients achieved a response in the first four cycles. Of the 180 cycles analyzed, only 50 (28%) had toxicity, and of these only 15 (8%) were grade iii-iv. The most common toxicity was diarrhea appearing in 18 patients. All patients received ambulatory treatment, except three of them who required hospitalization due to symptoms of their underlying disease. CONCLUSION: The combination of irinotecan and temozolomide is well tolerated and active against pediatric refractory or relapsed solid tumors.

Neutropenia e mucosite oral: fatores de risco para candidiase em crianças com câncer / Neutropenia and oral mucositis: risck factors for candidiasis in children with cancer

A mucosite oral (MO) representa uma complicação estomatológica desafiante em pacientes com câncer, a qual pode causar significativa morbidade e comprometimento dos protocolos de tratamento, podendo ainda representar um risco significativo de infecções oportunista, particularmente em pacientes neutropênicos. Mediante inspeção clinica foi avaliada a ocorrência de MO e candidíase em 40 crianças com neoplasias. A MO foi observada em 13 crianças com neoplasias sistêmicas (n = 25) e 3 com tumores sólidos (n = 15), sem diferença estatisticamente significativa na ocorrência desta complicação entre as crianças com neoplasias sistêmicas e aquelas com tumores sólidos (p = 1,69). Observou-se que 5 crianças em tratamento para neoplasias sistêmicas desenvolveram em conjunto 10 lesões de candidíase, porém sem diferença estatisticamente significativa na ocorrência desta infecção entre as crianças com neoplasias sistêmicas e aquelas com tumores sólidos (p = 0,08). Constatou- se a ocorrência de 26 (7,3%) episódios de neutropenia, sendo 5 destes associados à ocorrência candidiase, nenhum dos quais ocorreu associado à presença concomitante de MO. A neutropenia contribui para o desenvolvimento de candidíase, a qual pode ser agravada pela falta de higiene oral, entre outros fatores.

The oral mucositis (OM) is a challenging stomatologic complication in patients with cancer, which may cause significant morbidity and impairment of treatment protocols and may represent a significant risk of opportunistic infections, particularly in neutropenic patients. Upon inspection clinic was assessed the occurrence of OM and candidiasis in 40 children with malignancies. By hematologic laboratorial exam was availed de absolute neutrophil count (ANC). The OM was observed in 13 children with systemic neoplasms (n = 25) and 3 with solid tumors (n = 15), no statistically significant difference was observed in the occurrence of this complication among children with systemic malignanciesand those with solid tumors (p = 1, 69). It was observed that 5 children in treatment for systemic cancers developed together 10 lesions of candidiasis, but no statistically significant difference was observed in the occurrence of this infection among children with systemic malignancies and those with solid tumors (p = 0.08). It was observed the occurrence of 26 (7.3%) episodes of neutropenia, 5 of them associated with the occurrence of candidiasis, none of which were associated with concomitant presence of OM. The neutropenia contributes to the development of candidiasis, which may be aggravated by defficient oral hygiene, among other factors.

Mieloptisis. Viejos aspectos, nuevos conceptos / Myelophthisis. Old aspects, new concepts

Introducción: la mieloptisis es la infiltración de la médula ósea por células no hematopoyéticas.Objetivo: realizar un análisis detallado de 89 sujetos con mieloptisis tratados entre 1991 y 2006.Material y métodos: se revisaron las historias clínicas de 138 pacientes en quienes se encontró leucoeritroblastosis. De éstos, se seleccionaron 89 sujetos mayores de 16 años, con diagnóstico de alguna neoplasia sólida y mieloptisis.Resultados: la edad promedio fue 47,5 ± 17,2 años, la distribución por sexo fue homogénea y el 62 por ciento tuvo un IK ≥60 por ciento. Veintisiete pacientes (30 por ciento) tenían cáncer de mama, patología seguida por los tumores de primario desconocido (27 por ciento), el rabdomiosarcoma (10 por ciento), adenocarcinoma de próstata (10 por ciento), el carcinoma gástrico (7 por ciento) y otras neoplasias sólidas (22 por ciento). En el momento en que se documentó la mieloptisis, 72 por ciento y 50 por ciento tenían metástasis óseas y viscerales, respectivamente; 81 pacientes presentaron anemia (Hb 9,8 ± 1,2 gr/dl), la mediana del recuento plaquetario fue 174.000 y el promedio de leucocitos 24.283 ± 5.447. Cuarenta y tres pacientes recibieron quimioterapia después del diagnóstico de infiltración medular, tras lo que se evidenció normalidad en el recuento leucocitario en 40 por ciento de los casos. Se presentaron nueve episodios de neutropenia febril, la mediana de supervivencia global (SG) a partir del diagnóstico de la neoplasia fue 13,8 meses, y después de la mieloptisis, 2,2 meses. Los factores relacionados con una menor supervivencia fueron: la presencia de Hb ≤8,5 gr/dl (HR: 0,54, IC95 por ciento 0,32-0,95; p = 0.04), >3 sitios de metástasis (HR: 0,67, IC95 por ciento 0,45-0,92; p = 0.03), enfermedad visceral (HR: 0,72, IC95 por ciento 0,66-0,89; p = 0.04) y la neutropenia febril por quimioterapia (HR: 0,52, IC95 por ciento 0,37-0,60; p = 0.02).Conclusiones: la mieloptisis es una condición grave que modifica la SG de los pacientes con tumores sólidos. El tratamiento de este subgrupo debe seleccionarse teniendo en cuenta su toxicidad hematológica.

O transplante de células-tronco hematopoéticas como opção no tratamento de doenças não hematológicas: [revisão] / Hematopoietic stem cell transplant: a therapeutic option for non-hematologic diseases: [review]

Nesta revisão são abordadas as doenças em que existem dados e perspectivas do uso de transplante de células-tronco hematopoéticas em suas diversas modalidades. São apresentados também os aspectos referentes aos regimes de condicionamento empregados, e sua relação com toxicidade e taxa de mortalidade ligadas ao transplante. São apresentadas as doenças autoimunes e particularizados dados específicos do lúpus eritematoso sistêmico, esclerose sistêmica e esclerose múltipla e diabetes mellitus tipo 1. A base do procedimento nas doenças autoimunes é a reprogramação imunológica. Aparentemente o procedimento tem sua indicação nas doenças em que os tratamentos convencionais de imunossupressão tenham falhado, e o dano orgânico não tenha sido definitivo, mas tenha chance de ocorrer caso não seja realizado o transplante. A modalidade aparentemente indicada no momento deve ser o transplante de células-tronco autogênico com regimes de condicionamento não mieloablativo para se obter sobrevivência estimada em mais de 50 por cento em todas as doenças, com baixa toxicidade e com mortalidade nula ligada ao transplante. São apresentados também os resultados nos tumores sólidos, que são discutíveis, e particularidades no câncer de mama. A aparente indicação para os tumores sólidos é transplante de células-tronco alogênico e se baseia no tratamento intensivo com doses mieloablativas com a finalidade de se induzir o efeito enxerto contra o tumor. Os regimes não mieloablativos são preconizados com a finalidade de redução da toxicidade e indução de imunossupressão, sendo os dados insuficientes e discutíveis, o que obriga a introdução de novas estratégias terapêuticas baseadas na terapia imune e celular.

In this report we discuss data and perspectives of hematopoietic stem cell transplantation in non-hematologic diseases. Aspects related to the conditioning regimen and its relationship with toxicity and mortality are also presented. Specific autoimmune diseases are discussed, in particular systemic lupus erythematosus, systemic sclerosis, multiple sclerosis and type 1 diabetes mellitus. The aim of the procedure in autoimmune diseases is immune reprogramming. Apparently this procedure has indications for diseases in which conventional treatments have failed when organ damage is not definitive, but likely to occur if transplantation is not performed. The most promising method appears to be autologous stem cell transplantation with non-myeloablative conditioning regimens to obtain survival that is estimated at more than 50 percent for all autoimmune diseases, with low toxicity and no mortality related to transplantation. The controversial results of solid tumor treatment and particularities of breast cancer are also presented. Hematopoietic stem cell transplantation is the apparent indication for solid tumors based on intensive treatment with myeloablative doses in order to induce the graft versus tumor effect. The myeloablative conditioning regimens are introduced with the purpose of reducing the toxicity and inducing immunosuppression but the data are insufficient and questionable requiring the introduction of new therapeutic strategies based on cellular and immune therapy.

Avaliações de indicadores de cuidado de pacientes pediátricos terminais com tumores sólidos no Instituto Nacional de Câncer

Objetivo: Avaliar o cuidado de crianças com tumores sólidos incuráveis que morrem por progressão e/ou complicações terapêuticas, usando indicadores de cuidados no fim da vida. Métodos: Os dados foram coletados retrospectivamente de 207 prontuários de crianças com de tumores sólidos que morreram de 1999 a 2004, HCI- INCA. Variáveis: sexo, idade, data óbito, laudohistopatológico, estadia, número esquemas de quimioterapia, data último esquema e da última aplicação de QT, local do óbito, média de dias hospitalizados, número de episódios de hospitalização, número de consultas emergência, dias na UTI pediátrica no último mês, média de dias entre o óbito e o último esquema e última aplicação de quimioterapia. Estes dados foram utilizados para medir e comparar com os indicadores de qualidade de cuidado no fim da vida propostos por Earle et coIs para adultos portadores de neoplasias, divididos em três grupos: supertratamento no fim da vida, qualidade do planejamento do cuidado e qualidade do cuidado na morte propriamente dita. Resultados: Foram do sexo masculino: 54,6%. Os óbitos oCOrreram como conseqüência de progressão de doença em 91,8% e por complicações do tratamento em 8,2%. Locais do óbito: 88,9% foram no hospital e 8,7% foram na residência. Indicadores: 1) Indicadores de supertratamento no fim da vida: 18% fizeram quimioterapia nos últimos 14 dias (risco atribuível-RA, comparando com Earle: 0,86) e 8,7% começaram um novo esquema de QT nos últimos 30 dias (RA:3,35). A média de dias entre o último esquema de quimioterapia e a morte foi de 213,2 dias (mediana 121) e a média de dias entre a última aplicação de quimioterapia e a morte foi de 112,7 dias (mediana 43). 2.) Indicadores de Qualidade de Planejamento do Cuidado: No último mês de vida 53,6% tiveram mais de uma consulta na emergência (RA: 12,4), 23,7% tiveram mais de uma internação no hospital (RA:4,9) e a média de dias hospitalizados foi de 9,12. Foram admitidos na UTI pediátrica 23,2% (RA:4,32) e a média de dias na UTI pediátrica no último mês foi de 1,69. 3.) Indicadores de Qualidade de Cuidado na Morte propriamente dita: 100% dos pacientes não foram encaminhados a estrutura de cuidados paliativos (hospice). (RA:I,22) e 22,7% morreram na UTI pediátrica ou na emergência (RA:0,33). Conclusões: Crianças que morreram de câncer apresentaram indicadores de cuidados no fim da vida mais elevados e mais agressivos que os benchmarks prospostos por Earle para adultos com câncer. Estudos devem ser feitos para avaliar o real benefício de procedimentos terapêuticas que possam causar sofrimento as crianças no fim da vida

Purpose: To evaluate the pattern of care of children with incurable solid tumors that die of progressive disease and/or therapeutic complications, applying end of life care indicators proposed by Earle et cols for adults with malignant diseases. Casuistics and Methods: Data were retrospectively collected from 207 charts of children with solid tumors that died between 1999 and 2004, HCI- INCA. Variables: sex, age, date of death, histopathological diagnosis, stage, number of chemotherapy treatments, last schedule and last chemotherapy application date, place of death, mean hospitalization days, number of hospitalization episodes, number of emergency consultations, pediatric intensive care unit (PICU) days in the last month, mean days interval between last cycle and application of chemotherapy and death. These data were utilized to measure and to compare with indicators of quality of end of life care classified into three groups: End of life overtreatment, quality of care planning and quality of death care. Results: Male: 54.6%. Death due to disease progression: 91.8% and to treatment complications: 8,2%. Place of death: 88.9% in the hospital and 8.7% at home. 1) End of Life overtreatment Indicators: 18% received chemotherapy during the last 14 days (Attributable Risk-AR compared with Earle: 0.86) and 8.7% started a new chemotherapy schedule in the last 30 days (AR: 3.35). Mean days between the last chemotherapy schedule and death: 213.2 days (median 121) and the last chemotherapy application and death: 112.7 days (median 43); 2) Quality of care planning indicators: In the last month of life, 53.6% had more than one emergency visit (AR: 12.4) and 23.7%, more than one hospital admission (AR: 4.9), and mean hospitalization days was 9.12. Last month admission to the ICU: 23.2% (AR: 4.32) and last month mean days in the PICU: 1.69; 3) Quality of death care indicators: Patients had not been referred systematically to palliative care structure(Hospice) (AR: 1.22) e 22.7% died in the PICU or emergency room (AR: 0.33). Conclusion: Children who died of cancer, received more aggressive treatment when compared to indicators suggested by Earle et cols for adults with cancer. Studies should be performed to evaluate the real benefit of therapeutic procedures that can bring suffering to children in the last month of life

Revisión de Tema: Citogenética de tumores sólidos / Cytogenetics of solid tumors

El análisis citogenético de tumores ha proporcionado valiosa información sobre la biología del cáncer. Se ha establecido que más de la mitad de los tumores sólidos presentan alteraciones cromosómicas; por lo tnato, el análisis citogenético es de gran utilidad para el diagnósticos y el pronóstico. La identificación de cambios cromosómicos específicos recurrentees en numerosos tumores se considera un indicador de importancia clínica. Los estudios en este campo han revelado cerca de 100.000 alteraciones cromosómicas en más de de 30.000 neoplasias humanas. Sin embargo, los tumores sólidos son los menos caracterizados citogenéticamente, sólo una tercera parte del totalde ellos, debido a problemas técnicos en los cultivos celulares. La citogenética convencional ha sido muy útil para la posterior caracterización molecular de nuevos oncogenes y genes supresores de tumores involucrados en la génesis tumoral. En esta revisión se presentan algunos aspectos relacionados con el cáncer de etiología cromosómica, tipos de alteraciones cromosómicas, origen, frecuencia, técnicas modernas para su estudio, así como el impacto en el diagnóstico y el pronóstico del cáncer.